12 completed, 1 unknown, 1 withdrawn. 14 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 12, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow olaratumab: new trials by email Literature Review of olaratumab trials Research Report on olaratumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma Trabectedin, Doxorubicin, Olaratumab - Leiomyosarcoma | Phase 1 | Withdrawn | University of Miami | 2019-06-01 | 2019-03-18 | |
| Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients Olaratumab and Trabectedin - Sarcoma, Soft Tissue | Phase 1 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 28 | 2018-09-21 | 2023-03-27 |
| A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Doxorubicin, Ifosfamide - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 24 | 2017-10-18 | 2020-09-10 |
| A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Olaratumab, Pembrolizumab (KEYTRUDA®) - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 41 | 2017-07-03 | 2024-10-23 |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Olaratumab, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 184 | 2017-06-22 | 2022-06-28 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma Olaratumab, Doxorubicin, External Beam Radiotherapy - Soft Tissue Sarcoma | Phase 1 | Completed | Eli Lilly and Company | 51 | 2016-10-11 | 2019-08-12 |
| A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer Olaratumab, Doxorubicin, Vincristine - Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 68 | 2016-08-29 | 2020-05-20 |
| A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Olaratumab, Gemcitabine, Docetaxel - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 310 | 2016-03-01 | 2022-05-09 |
| A Study of Olaratumab in Japanese Participants With Advanced Cancer Olaratumab, Doxorubicin - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 25 | 2015-03-23 | 2021-02-17 |
| A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma Olaratumab, Doxorubicin - Sarcoma, Soft Tissue | Phase 1 | Completed | Eli Lilly and Company | 49 | 2015-01-22 | 2019-11-21 |
| A Study of Olaratumab in Soft Tissue Sarcoma Olaratumab, doxorubicin - Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 148 | 2010-10-01 | 2017-04-14 |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors Olaratumab - Malignancy, Metastasis | Phase 1 | Completed | Eli Lilly and Company | 16 | 2010-09-01 | 2017-04-14 |
| Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available IMC-3G3 - Solid Tumors | Phase 1 | Completed | Eli Lilly and Company | 20 | 2006-12-01 | 2011-06-28 |
Sarcoma (8) · Neoplasms (3) · Neoplasm Metastasis (2) · Leiomyosarcoma (1) · Lymphoma (1) · Pancreatic Neoplasms (1)
Eli Lilly and Company (11) · Grupo Espanol de Investigacion en Sarcomas (1) · Presage Biosciences (1) · University of Miami (1)
United States (10) · Spain (4) · France (3) · Germany (3) · Italy (3) · Japan (3) · United Kingdom (2) · Australia (1) · Belgium (1) · Denmark (1) · Hungary (1) · Israel (1) · Poland (1)
Gary Deutsch, MD (1) · Kenneth Gundle, MD (1) · Marilyn Huang, MD, MS (1) · Seth Pollack, MD (1)
2016 (3), 2015 (2), 2017 (1)